BCR-ABL TKI (specialist)
Dasatinib
Brand names: Sprycel
Adult dose
Dose: 100mg OD (CML chronic phase); 140mg OD (advanced phase / Ph+ ALL)
Route: Oral
Frequency: OD
Clinical pearls
- NICE TA425 / TA451: chronic-phase CML 1st/2nd-line; Ph+ ALL with chemotherapy
- BSH CML / ESMO
- Echo and ECG baseline; pleural effusion screening at each visit
Contraindications
- Hypersensitivity
Side effects
- Pleural effusion (often dose-related, may need diuretics or dose reduction)
- Pulmonary arterial hypertension (rare)
- Cytopenias
- Bleeding
- QT prolongation
- Diarrhoea
- Cardiac dysfunction
Interactions
- Strong CYP3A4 inhibitors/inducers
- Acid-suppressants
- QT-prolonging drugs
Monitoring
- FBC
- BCR-ABL
- ECG
- Echo
- Pleural effusion
- LFTs
Reference: BNF; NICE TA425; BSH CML guidelines; ESMO; SmPC; https://bnf.nice.org.uk/drugs/dasatinib-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Acute Myeloid Leukaemia Presentation · BSH; NICE — NG146
- Tumour Lysis Syndrome · Cairo-Bishop; BSH; NICE — Best Practice
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158